The biotechnology sector, as measured by the XBI ETF, is down over 3% in the current trading session without a clear, identifiable catalyst. While there was some negative news from individual companies, such as a failed clinical trial for Karyopharm Therapeutics after the market closed yesterday, none of these events appear significant enough to cause a sector-wide drop of this magnitude. The decline may be attributable to broader market weakness or a rotation out of the high-growth sector, but specific news supporting this is not prominent.